# RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring

> **NCT05292209** · PHASE2 · RECRUITING · sponsor: **University of Utah** · enrollment: 78 (estimated)

## Conditions studied

- Atrial Fibrillation Paroxysmal

## Interventions

- **DRUG:** Riluzole 50 MG

## Key facts

- **NCT ID:** NCT05292209
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-15
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2023-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05292209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05292209, "RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05292209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*